Amgen’s KRAS-blocking drug data are strong, but raise new questions

Amgen’s KRAS-blocking drug data are strong, but raise new questions

STAT Plus: Data on Amgen’s KRAS-blocking cancer drug are encouraging, but also raise new questions

By ADAM FEUERSTEIN

ADOBE

Cancer scientists and investors alike are excited about the first tumor-shrinking results from a medicine targeted against the “undruggable” KRAS protein.

READ MORE